開拓藥業(09939.HK)ALK-1抗體聯合治療法總體緩解率達40%
開拓藥業(09939.HK)公布,其ALK-1抗體GT90001聯合Nivolumab二線治療晚期肝細胞癌(HCC)患者II期臨床試驗,積極資料已在2021年美國臨床腫瘤學會胃腸道腫瘤研討會上發佈,結果顯示聯合療法的療效令人鼓舞且安全性良好。有效性方面,患者總體緩解率為40%,有8例患者出現部分緩解,目前已有2例患者治療時間超過1年。
開拓藥業董事長兼首席執行官童友之表示,將在中國和美國積極佈局開展多個治療晚期HCC的國際多中心的II/III期臨床試驗,同時對治療其它實體瘤進行探索,使更多腫瘤患者受益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.